Study Title
Usefulness of Tumor Heterogeneity Assessment in Patients With MCRPC Undergoing Radioligand Therapy With 177LU-PSMA-617 Using Serial 18F-DCFPYL, 18F-FDG and 18F-Fluciclovine PET/CT Predicting Clinical Outcome
Study Details
Description:
The imaging analysis will consist in obtaining quantitative measurements of lesion uptake on the pre- and post-LuPSMA RLT (lesion and whole-body SUVmax, SUVmean and tumor volume) at each time point on all PET/CT scans. PET metrics at the lesion- and whole-body level will be compared among different PET radiopharmaceuticals at the same time point, and changes over time will be assessed.
Sponsor:
VA Greater Los Angeles Healthcare System
Contacts:
Gholam Berenji, MDgholam.berenji@va.gov
310-268-3547
Janake Wijesuriya, BSjanake.wijesuriya@va.gov
310-977-5209
Government Study Link:
NCT06706921 - Click here to see study onClinicalTrials.gov
© 2021 XCancer Software LLC
Contact XCancer: 402-991-8468